Lurosetron
Clinical data
ATC code
  • none
Identifiers
  • 6-fluoro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H17FN4O
Molar mass312.348 g·mol−1
3D model (JSmol)
  • CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=C(N3C)C(=CC=C4)F
  • InChI=1S/C17H17FN4O/c1-10-13(20-9-19-10)8-22-7-6-14-15(17(22)23)11-4-3-5-12(18)16(11)21(14)2/h3-5,9H,6-8H2,1-2H3,(H,19,20) ☒N
  • Key:NUMKWGDDRWJQMY-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Lurosetron (INN) is a serotonin 5-HT3 receptor antagonist.[1]

Synthesis

Lurosetron synthesis[2]

References

  1. ↑ Prakash SP, Cable KM, Correa ID, Fellows L, Montgomery S, Newman JJ, Waterhouse L, Wells GN, Sutherland DR (1995). "Synthesis of isotopically labelled pyridoindolone 5-HT3 receptor antagonists". Journal of Labelled Compounds and Radiopharmaceuticals. 36 (10): 993–1007. doi:10.1002/jlcr.2580361011.
  2. ↑ EP 0353983, Coates, Ian Harold; Oxford, Alexander William & North, Peter Charles et al., published 1990-02-07, assigned to Glaxo Group Ltd.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.